参考文献/References:
[1]Lippi G,Sanchis-Gomar F,Cervellin G. Global epidemiology of atrial fibrillation:an increasing epidemic and public health challenge[J]. Int J Stroke,2021,16(2):217-221.[2]Du X,Guo L,Xia S,et al.Atrial fibrillation prevalence,awareness and management in a nationwide survey of adults in China[J]. Heart,2021,107(7):535-541.[3]Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2021,42(5):373-498.[4]Petrungaro M,Fusco L,Cavarretta E,et al. Long-term sports practice and atrial fibrillation:an updated review of a complex relationship[J]. J Cardiovasc Dev Dis,2023,10(5):218.[5]Correction to:managing atrial fibrillation in patients with heart failure and reduced ejection fraction:a scientific statement from the American Heart Association[J]. Circ Arrhythm Electrophysiol,2021,14(11):e000080.[6]Capilupi MJ,Kerath SM,Becker LB. Vagus nerve stimulation and the cardiovascular system[J]. Cold Spring Harb Perspect Med,2020,10(2):a034173.[7] Pan J,Wang W,Wu X,et al. Inflammatory cytokines in cardiac pacing patients with atrial fibrillation and asymptomatic atrial fibrillation[J]. Panminerva Med,2018,60(3):86-91.[8]Berg DD,Ruff CT,Morrow DA. Biomarkers for risk assessment in atrial fibrillation[J]. Clin Chem,2021,67(1):87-95.[9]Laish-Farkash A,Sevilya Z,Perelshtein Brezinov O,et al. Inflammatory cytokines differ between patients with high versus low CHA2DS2-VASc scores in sinus rhythm-a possible mechanism for adverse cardiovascular events[J].Int J Cardiol Cardiovasc Risk Prev,2022,15:200155.[10]Cabaro S,Conte M,Moschetta D,et al. Epicardial adipose tissue-derived IL-1β triggers postoperative atrial fibrillation[J]. Front Cell Dev Biol,2022,10:893729.[11]Heijman J,Muna AP,Veleva T,et al. Atrial myocyte NLRP3/CaMKⅡ nexus forms a substrate for postoperative atrial fibrillation[J]. Circ Res,2020,127(8):1036-1055.[12]Wu Q,Liu H,Liao J,et al. Colchicine prevents atrial fibrillation promotion by inhibiting IL-1β-induced IL-6 release and atrial fibrosis in the rat sterile pericarditis model[J]. Biomed Pharmacother,2020,129:110384.[13]Liao J,Zhang S,Yang S,et al. Interleukin-6-mediated-Ca2+ handling abnormalities contributes to atrial fibrillation in sterile pericarditis rats[J].?ront Immunol,2021,12:758157.[14] Dimosiari A,Patoulias D,Kitas GD,et al. Do interleukin-1 and interleukin-6 antagonists hold any place in the treatment of atherosclerotic cardiovascular disease and related co-morbidities? An overview of available clinical evidence[J]. J Clin Med,2023,12(4):1302.[15]Jia X,Cheng X,Wu N,et al. Prognostic value of interleukin-6 in atrial fibrillation:a cohort study and meta-analysis[J]. Anatol J Cardiol,2021,25(12):872-879.[16]Li C,Tong W,Liu B,et al. The -1082A＞G polymorphism in promoter region of interleukin-10 and risk of digestive cancer:a meta-analysis[J]. Sci Rep,2014,4:5335.[17]Kondo H,Takahashi N,Gotoh K,et al. Splenectomy exacerbates atrial inflammatory fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats:possible role of spleen-derived interleukin-10[J]. Heart Rhythm,2016,13(1):241-250.[18]Zheng DD,Ji SN,Chen C,et al. Association of interleukin-10 promotor polymorphisms with atrial fibrillation in Han Chinese[J]. Int J Clin Exp Med.,2014,7(11):4199-4206.[19]Murdaca G,Colombo BM,Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases[J]. Intern Emerg Med,2011,6(6):487-495.[20]Chen X,Zhang Y,Ding Q,et al. Role of IL-17A in different stages of ischemic stroke[J]. Int Immunopharmacol,2023,117:109926.[21]Xu L,Wang N,Liang Y,et al. Interleukin-17A contributes to atrial fibrillation recurrence and left atrial reservoir function after catheter ablation[J]. Pol Arch Intern Med,2019,129(6):432-435.[22]Xu L,Fan T,Liang Y,et al. Associations between interleukin 17A and left atrial spontaneous echo contrast in patients with non-valvular atrial fibrillation[J]. Pol Arch Intern Med,2022,132(6):16252.[23]Ye J,Ji Q,Liu J,et al. Interleukin 22 promotes blood pressure elevation and endothelial dysfunction in angiotensin Ⅱ-treated mice[J]. J Am Heart Assoc,2017,6(10):e005875.[24]Wu Y,Tan L,Shi L,et al. Interleukin-22 is elevated in the atrium and plasma of patients with atrial fibrillation and increases collagen synthesis in transforming growth factor-β1-treated cardiac fibroblasts via the JNK pathway[J]. Exp Ther Med,2020,20(2):1012-1020.[25]Gomez SE,Parizo J,Ermakov S,et al. Evaluation of the association between circulating IL-1β and other inflammatory cytokines and incident atrial fibrillation in a cohort of postmenopausal women[J]. Am Heart J,2023,258:157-167.[26]Liu Q,Zhang F,Yang M,et al. Increasing level of interleukin-1β in epicardial adipose tissue is associated with persistent atrial fibrillation[J]. J Interferon Cytokine Res,2020,40(1):64-69.?27]Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.[28]Weymann A,Popov AF,Sabashnikov A,et al. Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery:a systematic review and meta-analysis[J]. Kardiol Pol,2018,76(2):440-451.[29Psychari SN,Apostolou TS,Sinos L,et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation[J]. Am J Cardiol,2005,95(6):764-767.[30]Harada M,van Wagoner DR,Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management[J]. Circ J.,2015,79(3):495-502.[31]Chung MK,Martin DO,Sprecher D,et al. C-reactive protein elevation in patients with atrial arrhythmias:inflammatory mechanisms and persistence of atrial fibrillation[J]. Circulation,2001,104(24):2886-2891.[32]Singleton MJ,Yuan Y,Dawood FZ,et al. Multiple blood biomarkers and stroke risk in atrial fibrillation:the REGARDS study[J]. J Am Heart Assoc,2021,10(15):e020157.[33]Zhou P,Waresi M,Zhao Y,et al. Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation:a systematic review and meta-analysis[J]. Rev Port Cardiol (Engl Ed),2020,39(12):723-728.[34]Xue H,Lin B,An J,et al. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk[J]. BMC Cancer,2012,12:102.[35]Krishnamurthy P,Rajasingh J,Lambers E,et al. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR[J]. Circ Res,2009,104(2):e9-e18.[36]Ouyang W,Rutz S,Crellin NK,et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease[J]. Annu Rev Immunol,2011,29:71-109.[37]Watanabe H,Tanabe N,Watanabe T,et al. Metabolic syndrome and risk of development of atrial fibrillation:the Niigata preventive medicine study[J]. Circulation,2008,117(10):1255-1260.[38]Iyer SS,Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease[J]. Crit Rev Immunol,2012,32(1):23-63.[39]Rafaqat S,Sharif S,Majeed M,et al. Biomarkers of metabolic syndrome:role in pathogenesis and pathophysiology of atrial fibrillation[J]. J Atr Fibrillation,2021,14(2):20200495.[40]Fu XX,Zhao N,Dong Q,et al. Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis[J]. Int J Mol Med,2015,36(1):83-92.[41]Yue H,Gu J,Zhao X,et al. Role of the interleukin-17 pathway in the pathogenesis of atrial fibrillation associated with inflammation[J]. Arch Med Sci,2021,17(1):262-265.[42]Ye J,Wang M,Jiang H,et al. Increased levels of interleukin-22 in thoracic aorta and plasma from patients with acute thoracic aortic dissection[J]. Clin Chim Acta,2018,486:395-401.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(4):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(4):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(4):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(4):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(4):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]孙静美 尹德春 曲秀芬.炎症信号与心房颤动[J].心血管病学进展,2020,(1):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]
SUN Jingmei,YIN Dechun,QU Xiufen.Inflammatory Signals Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(4):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]